Biodexa Pharmaceuticals Plc (BDRX)

Biodexa Pharmaceuticals Balance Sheet

Financials in millions GBP. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	3.23	8.53	1.67	5.97	2.84	10.06
Cash & Short-Term Investments	3.23	8.53	1.67	5.97	2.84	10.06
Cash Growth	-19.97%	411.32%	-72.05%	110.54%	-71.80%	33.28%
Accounts Receivable	2.94	0.04	0.01	-	0.33	0.03
Other Receivables	0.53	0.19	0.7	0.7	1.15	1.06
Receivables	3.46	0.22	0.72	0.7	1.48	1.1
Prepaid Expenses	-	3.69	6.43	0.36	0.38	0.61
Total Current Assets	6.69	12.44	8.81	7.03	4.69	11.76
Property, Plant & Equipment	0.02	0.09	0.32	0.57	0.83	1.15
Other Intangible Assets	6.01	5.65	5.65	2.94	0.01	-
Total Assets	12.72	18.18	14.78	10.54	5.53	12.91

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	1.64	0.1	0.71	0.31	0.34	0.49
Accrued Expenses	-	1.86	1.27	0.86	0.82	0.55
Short-Term Debt	-	-	0.43	-	-	-
Current Portion of Leases	-	0.06	0.18	0.17	0.16	0.15
Current Income Taxes Payable	-	0.05	0.05	0.06	0.08	0.06
Current Unearned Revenue	-	0.57	1.47	-	0.2	-
Other Current Liabilities	1.14	3.5	0.93	4.17	0.31	0.61
Total Current Liabilities	2.78	6.13	5.03	5.57	1.9	1.84
Long-Term Leases	-	-	0.12	0.3	0.46	0.62
Other Long-Term Liabilities	0.33	0.65	1.31	-	-	-
Total Liabilities	3.11	6.77	6.46	5.86	2.36	2.46

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	14.25	0.23	0.33	1.19	0.11	0.1
Additional Paid-In Capital	99.79	98.92	93.12	86.73	83.67	83.43
Retained Earnings	-157.6	-155.81	-150.42	-144.77	-135.34	-127.8
Comprehensive Income & Other	53.18	68.06	65.29	61.52	54.72	54.72
Shareholders' Equity	9.61	11.41	8.32	4.68	3.16	10.45
Total Liabilities & Equity	12.72	18.18	14.78	10.54	5.53	12.91

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	-	0.06	0.73	0.46	0.62	0.77
Net Cash (Debt)	3.23	8.47	0.94	5.51	2.21	9.29
Net Cash Growth	-8.63%	799.47%	-82.89%	148.96%	-76.19%	27.52%
Net Cash Per Share	-	77.22	-	-	-	-
Filing Date Shares Outstanding	-	0.65	0.05	-	-	-
Total Common Shares Outstanding	-	0.45	0.01	-	-	-
Working Capital	3.91	6.31	3.78	1.46	2.79	9.92
Book Value Per Share	-	25.25	622.35	-	-	-
Tangible Book Value	3.6	5.76	2.68	1.74	3.16	10.45
Tangible Book Value Per Share	-	12.75	200.12	-	-	-
Machinery	-	0.16	0.77	1.52	1.59	1.87
Leasehold Improvements	-	0.05	0.05	0.05	0.05	0.05

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Mar 27, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Sep 16, 2026

Data Sources Report a data error